EQT AI Infrastructure Fund Reaches $11.5 Billion in NAV
Oct 15, 2026
Data Centers
EQT Life Sciences and Nextech Lead $183 Million Series C for Electra Therapeutics
Oct 22, 2025
Electra Therapeutics has raised $183 million in a Series C financing co-led by EQT Life Sciences and Nextech, with participation from Sanofi and other investors, to advance its immunology and cancer programs.
Electra Therapeutics has raised USD 183 million in Series C financing co-led by EQT Life Sciences and Nextech, with participation from Sanofi, HBM Healthcare Investments, Mubadala Capital, and existing investors, announced in a press release.
The funding will support a registrational Phase 2/3 clinical study of Electra’s lead program, ELA026, in secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no approved therapies. The study aims to confirm earlier Phase 1b results showing 100 percent survival at 8 weeks in frontline-treated patients.
Electra will also use the proceeds to expand ELA026 into hematologic cancers and to advance its second program, ELA822, which targets immune-mediated diseases. ELA026 has received FDA Breakthrough Therapy and EMA Priority Medicines designations for sHLH.
EQT Life Sciences partner Christoph Broja will join Electra’s board as an observer, supporting the company’s ongoing clinical and development initiatives.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 16 RapidCanvas Raises $29 Million to Expand Enterprise AI Platform Oct 16 KBRA Rated Anthropic BB+ Before $35 Billion Chip Financing Oct 16 Goodweek Raises $12 Million for AI Management Platform Oct 16 Intuit Agrees to Acquire AI Billing Startup Sequence for Reported $200 Million Oct 16 Matters Raises $5 Million to Build AI Consumer BankMore from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsFree newsletter
AI Funding Brief
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Enveda Raises $311 Million for AI Drug Discovery
Sep 24, 2026
Funding
Healthleap Raises $38 Million for Hospital Risk Screening AI
Oct 07, 2026
Funding
NAVER D2SF Backs ImpriMed in $10 Million Bridge Round
Sep 19, 2026
Funding
EliseAI raises $350 million at $4 billion valuation
Sep 30, 2026
Funding
ElevenLabs Closes $300 Million Tender at $22 Billion Valuation
Oct 01, 2026
Funding
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.